PATENT CLAIM ANALYSIS

Application Number: 15952017
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["548", "112000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 22):
The method of  claim 15 , wherein an amount of a non-steroidal anti-inflammatory drug that is orally administered to the human being is reduced after the dosage form comprising the zoledronic acid in the acid form or the salt form is orally administered.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.25
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15385415', '15348842', '15439774', '15354908', '15623274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.800269174999101
- 35 USC 102 Novelty (BERT): 0.6352751760954061
- Combined Prediction Score: 0.7837697751087315
- Mean Citation Score: 673.67468
- Max Citation Score: 681.28015
- Similarity Product: 535.9277319231479

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test